GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Is Stem Cell Therapy?

Stem cell therapy is a treatment in which a patient receives stem cells, or cells developed from them, to treat a specific disease. A well-established example is a blood stem cell transplant: the cells rebuild blood-cell production after intensive cancer treatment. Stem cell transplant The term also covers experimental and unproven interventions; it does not mean every treatment offered under that name is effective or approved. Important patient and consumer information about regenerative medicine therapies

How does stem cell therapy work?

Stem cells can make more stem cells and develop into cells with specific jobs. Stem Cell Blood-forming stem cells are also called hematopoietic stem cells. In a transplant, infused cells travel to the bone marrow, where they can produce red blood cells, white blood cells and platelets. In cancer care, the transplant usually supports recovery from treatment rather than attacking cancer directly. In leukemia, donor immune cells may also attack cancer cells left behind. Stem cell transplant

What Is Stem Cell Therapy?

Transplant cells come from the bloodstream, bone marrow or umbilical cord blood. The distinction between autologous and allogeneic stem cells is their source: an autologous transplant uses your own cells; an allogeneic transplant uses a donor’s. The transplant team checks how closely a donor matches the recipient. Stem cell transplant

What can stem cell therapy treat?

Blood stem cell transplants are used for selected patients with leukemia, lymphoma, multiple myeloma, aplastic anemia or sickle cell disease. Doctors assess the disease, previous treatment, donor options and the patient’s ability to tolerate the procedure. Stem cell transplant

Ryoncil is a different cell therapy: it contains mesenchymal stromal cells (MSCs) from healthy adult donors’ bone marrow. The U.S. Food and Drug Administration (FDA) approved it on December 18, 2024, for children aged 2 months and older with steroid-refractory acute graft-versus-host disease. This complication can occur after a donor blood stem cell transplant; “steroid-refractory” means it has not responded to steroid treatment. Ryoncil’s approval does not establish effectiveness or approval for other MSC products or uses. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

Is every treatment offered by a clinic approved?

No. The FDA warns about unapproved regenerative products offered outside FDA-overseen clinical trials in the United States. Being available at a clinic does not establish approval or effectiveness. Important patient and consumer information about regenerative medicine therapies In Japan, provision plans for medical practice and research follow a separate regulatory pathway from product marketing approval. 0003 A public listing under Japan’s regenerative medicine registration system is not proof of effectiveness or product marketing approval. 0000186471 0003

What happens during treatment?

The U.S. National Cancer Institute (NCI) describes these stages for blood stem cell transplantation in cancer care. The schedule and intensity of preparatory treatment vary with the regimen and the patient’s health. Stem cell transplant

NCI estimates for blood stem cell transplantation
StageTime estimateWhat it means
Preparatory treatment1–2 weeksIn the high-dose regimen described by NCI, chemotherapy, sometimes with radiation, comes before the transplant. Some regimens use lower doses.
Stem cell infusion1–5 hoursThe cells are given through an IV catheter. Preparation and recovery take additional time.
Full immune recovery after an autologous transplantSeveral monthsYour blood counts can recover before your immune defenses fully recover.
Full immune recovery after an allogeneic or identical-twin transplantAbout 1–2 yearsHospital discharge and return to work have separate timelines.

These estimates describe blood stem cell transplantation, not recovery from MSC injections or other regenerative procedures. Stem cell transplant

What are the risks?

Blood stem cell transplantation and its preparatory treatment can cause serious infection, bleeding, infertility and organ damage. After a donor transplant, graft-versus-host disease can occur when donor immune cells attack the recipient’s tissues. Stem cell transplant

The FDA has received reports of blindness, tumors and serious infections after unapproved regenerative products. Using your own cells does not remove the risk of contamination or unwanted immune reactions. These reports cannot tell you how often complications occur across all cell therapies. Important patient and consumer information about regenerative medicine therapies

Common adverse reactions reported in the Ryoncil study included infections, fever and bleeding. The FDA also warns about hypersensitivity and acute infusion reactions, transmission of infectious agents and tissue forming where it does not belong. These risks concern Ryoncil, not a uniform risk profile for all MSC therapies. Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

How do I assess a proposed treatment?

Comparing the NCI transplant guide with the FDA’s Ryoncil announcement shows a practical distinction: both treatments deliver cells through a vein, but they use different cells for different purposes. An “IV stem cell treatment” is therefore not a precise treatment description. Ask for the cell type, product or procedure name, and intended use before comparing results. Stem cell transplant Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host

  • What regulatory pathway allows this treatment here, and what is its approval or research status for my condition?
  • Which human study matches my diagnosis, disease stage and proposed treatment? Ask for the trial phase, number of patients, comparison group, measured outcomes, length of follow-up and reported side effects.
  • What standard treatments could I choose instead, and who will handle complications and follow-up?

A trial registration records a study; it does not prove that the treatment works. Listing a product on ClinicalTrials.gov does not establish FDA authorization to market it. Important patient and consumer information about regenerative medicine therapies PubMed inclusion does not mean the National Library of Medicine endorses the findings or has judged the individual study’s quality. Disclaimer

Questions about arranging a consultation in Japan?

Ask the patient support team about appointment arrangements, language support and which records to prepare. Treatment suitability is assessed by a physician.

Contact Patient Support